Holen Sie sich die Stockscreener-App
69.17
1.43%
-1.00
Handel nachbörslich:
69.40
0.23
+0.33%
Schlusskurs vom Vortag:
$70.17
Offen:
$70.03
24-Stunden-Volumen:
16.01M
Relative Volume:
1.13
Marktkapitalisierung:
$102.80B
Einnahmen:
$20.08B
Nettoeinkommen (Verlust:
$2.89B
KGV:
35.67
EPS:
1.9391
Netto-Cashflow:
$3.66B
1W Leistung:
-0.45%
1M Leistung:
-9.99%
6M Leistung:
-29.55%
1J Leistung:
-31.38%
1-Tages-Spanne:
$68.85
$70.13
1-Wochen-Bereich:
$68.03
$71.20
52-Wochen-Spanne:
$67.56
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
69.17 | 102.80B | 20.08B | 2.89B | 3.66B | 1.9391 |
ABT
Abbott Laboratories
|
103.99 | 180.70B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.44 | 125.40B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
EW
Edwards Lifesciences Corp
|
79.34 | 45.74B | 6.07B | 1.06B | 1.34B | 1.8063 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-03 | Herabstufung | Erste Group | Buy → Hold |
| 2025-09-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-16 | Hochstufung | Needham | Hold → Buy |
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
Boston Scientific at American College of Cardiology: Clinical Trials Drive Growth - Investing.com
Boston Scientific Unveils “Practice-Transforming” Trial Data for PE and AF at ACC Conference Call - Yahoo Finance
One-time heart implant cut bleeding vs. blood thinners in 3,000-patient trial - Stock Titan
HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism – Company AnnouncementFT.com - Financial Times
25,000 Shares in Boston Scientific Corporation $BSX Bought by Waycross Partners LLC - MarketBeat
Boston Scientific Corp (NYSE:BSX) Presents a Compelling Mix of Strong Fundamentals and Technical Breakout Potential - ChartMill
Avity Investment Management Inc. Has $20.76 Million Stock Holdings in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
Boston Scientific (NYSE:BSX) Cut to "Hold" at Wall Street Zen - MarketBeat
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch
BSX Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Bernstein reiterates Boston Scientific stock rating ahead of trial data - Investing.com
BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit - Barchart.com
Boston Scientific Corp Stock (BSX) Moved Up by 3.66% on Mar 26: Key Drivers Unveiled - TradingKey
Boston Scientific Corp. Stock: Navigating Electrophysiology Challenges Amid Strong Cardiovascular Gr - AD HOC NEWS
Portnoy Law Firm Announces Class Action on Behalf of Boston Scientific Corporation Investors - GlobeNewswire Inc.
BOSTON SCIENTIFIC CORPORATION (BSX) SHAREHOLDER ALERT - GlobeNewswire
Why The Narrative Around Boston Scientific (BSX) Is Shifting As Analysts Reset Expectations - Yahoo Finance
SG Americas Securities LLC Sells 19,225 Shares of Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corp. stock faces pressure amid medtech sector slowdown and pipeline delays - AD HOC NEWS
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Boston Scientific Corp. stock outperforms competitors on strong trading day - MarketWatch
BSX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Boston Scientific (BSX): Company Profile, Stock Price, News, Rankings - Fortune
Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade) - Seeking Alpha
Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX - ChartMill
Is Boston Scientific Corporation (BSX) A Good Stock To Buy Now? - Insider Monkey
Boston Scientific Corp. stock shows resilient fundamentals amid volatile medtech market pressures - AD HOC NEWS
Why Boston Scientific's Big Dip Could Be a Bigger Opportunity - The Globe and Mail
BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - GlobeNewswire Inc.
Deadline Alert: Boston Scientific Corporation (BSX) - GlobeNewswire
A Quick Look at Today's Ratings for Boston Scientific(BSX.US), With a Forecast Between $90 to $120 - 富途牛牛
BSX Shareholder Alert: Boston Scientific Corporation Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - Barchart
Evercore ISI reiterates Boston Scientific stock rating on growth outlook - Investing.com UK
Evercore ISI reiterates Boston Scientific stock rating on growth outlook By Investing.com - Investing.com India
Stifel reiterates Boston Scientific stock rating ahead of trial data - Investing.com
Boston Scientific (BSX) Joins Evercore's Tactical Outperform Lis - GuruFocus
Boston Scientific Corporation $BSX Shares Sold by Park Avenue Securities LLC - MarketBeat
BSX Stock Quote Price and Forecast - CNN
Avanza Fonder AB Acquires 21,210 Shares of Boston Scientific Corporation $BSX - MarketBeat
Robbins LLP Urges BSX Stockholders Who Lost Money Investing in Boston Scientific Corporation to Contact the Firm for Information About Leading the Class Action - Barchart.com
Westview Management dba Westview Investment Advisors Buys New Stake in Boston Scientific Corporation $BSX - MarketBeat
ROSEN, A RANKED AND LEADING FIRM, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
BSX INVESTOR ALERT: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law - The Norfolk Daily News
Boston Scientific (NYSE:BSX) Falls as Recall Draws S&P 500 Focus - Kalkine Media
Tounjian Advisory Partners LLC Makes New Investment in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific’s EMEA Urology Push May Reframe Valuation Story - simplywall.st
Is Boston Scientific (BSX) Still Attractive After Its Recent Share Price Pullback? - Yahoo Finance
BSX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026 - marketscreener.com
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Boston Scientific Corp-Aktie (BSX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 16 '26 |
Option Exercise |
0.00 |
905 |
0 |
6,433 |
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 14 '26 |
Option Exercise |
0.00 |
1,190 |
0 |
5,977 |
| O'Connor Padraig Andrew | EVP, Global Operations |
Feb 13 '26 |
Option Exercise |
0.00 |
500 |
0 |
4,986 |
| Woodworth Emily | SVP, Global Controller and CAO |
Feb 16 '26 |
Option Exercise |
0.00 |
637 |
0 |
2,676 |
| Woodworth Emily | SVP, Global Controller and CAO |
Feb 14 '26 |
Option Exercise |
0.00 |
661 |
0 |
2,335 |
| Woodworth Emily | SVP, Global Controller and CAO |
Feb 13 '26 |
Option Exercise |
0.00 |
1,413 |
0 |
2,364 |
| Monson Jonathan | EVP and CFO |
Feb 16 '26 |
Option Exercise |
0.00 |
990 |
0 |
38,426 |
| Monson Jonathan | EVP and CFO |
Feb 14 '26 |
Option Exercise |
0.00 |
1,058 |
0 |
37,906 |
| Monson Jonathan | EVP and CFO |
Feb 13 '26 |
Option Exercise |
0.00 |
1,766 |
0 |
37,636 |
| O'Sullivan Miriam | SVP, Chief HR Officer |
Feb 16 '26 |
Option Exercise |
0.00 |
990 |
0 |
17,593 |
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):